The short answer
Rare cancers are a quarter of all cancer cases but each one is uncommon. That produces slow diagnosis, thin evidence, few trials, long journeys and a specific kind of loneliness.
NCI defines a rare cancer as one affecting fewer than 40,000 people a year in the US; UK and EU definitions use fewer than 6 cases per 100,000 people per year.
Rare cancers collectively account for around a quarter of all cancer cases and around a quarter of cancer deaths.
For many rare tumours there is no standard of care, and recommendations rest on case series and expert consensus rather than randomised trials.
Fewer trials exist because patients are geographically dispersed and research funding is lower; the trial-design threshold in Europe is fewer than 2 cases per 100,000 a year.
Choose how you want to understand this
The full explanation.
What "rare" actually means
The National Cancer Institute defines a rare cancer as one affecting fewer than 40,000 people a year in the United States. Cancer Research UK reports that UK and EU experts instead use an incidence threshold of fewer than 6 cases per 100,000 people per year, with a stricter cut-off of fewer than 2 per 100,000 when designing clinical trials. By these definitions all childhood cancers are rare.
The collective figure is the part most people are not told: rare cancers together make up around a quarter of all cancer cases and around a quarter of cancer deaths. Rare cancer as a category is common. Any individual rare cancer is not, and that mismatch drives almost everything else that follows.
Why the diagnosis took so long
Rare tumours produce symptoms that are unusual or that resemble something benign, so they are investigated later. The pathology is harder: a general pathologist may see a given rare tumour once in a career, and confirming the diagnosis can require specialist review, additional immunohistochemistry or molecular testing, and consultation with colleagues at other hospitals or in other countries. Cancer Research UK lists exactly this sequence as a reason rare cancers take longer to diagnose.
Because the treatment plan is derived from the diagnosis, expert pathology review is usually the highest-value single step available. Asking for it is standard practice for rare tumours, not a challenge to the first pathologist.
No standard of care, and what to ask instead
Standards of care are built from randomised trials, and randomised trials need patients. For a tumour diagnosed in a few hundred people a year worldwide, that evidence has often never been generated. Recommendations are assembled from case series, registry data and expert consensus. Two specialists can therefore give different advice while both reasoning carefully from thin evidence.
The useful question is not "what is the standard treatment" but "what is this recommendation based on, and how confident are you." A clinician who answers that honestly is giving you more than one who produces false certainty.
Fewer trials, and further to travel
Cancer Research UK sets out why trials are scarcer: patients are geographically dispersed, few hospitals see enough cases to run a study, and research funding follows larger populations. What exists is often a basket trial recruiting by molecular feature rather than tumour type, a natural history study, or an early-phase study at a single centre. NCI's MyPART network runs a natural history study for rare solid tumours in children and adults and holds rare tumour clinics at the NIH Clinical Center.
Travel is a recognised burden. Referral to a centre that sees the tumour type routinely can mean hundreds of miles, repeated. It is worth asking whether the specialist centre will plan treatment while a local service delivers it.
The specific loneliness
Support groups fill with people who have common cancers and cannot follow the conversation. Nobody in the infusion suite has heard of your diagnosis. You spell the name each time you say it, including to clinicians. Online searching returns case reports rather than information written for patients, and survival figures derived from forty people. People say "at least it's treatable" with no reference point for whether that is true. Cancer Research UK states plainly that people with rare cancers can feel isolated and may never meet anyone else with the same type.
Some routes exist against that. Attending a specialist centre concentrates patients and raises the chance of meeting someone. Most rare tumour types have a disease-specific foundation or a patient registry, and these are the fastest way to reach both current evidence and other patients. In the UK, Cancer52 is an alliance representing rare and less common cancer charities; in Europe, the EURACAN reference network links specialist centres. Asking your team to name the foundation or registry for your specific diagnosis is a reasonable request.
Sources
Words to know
Tap any term to see what it means.
Common questions
What counts as a rare cancer?
Definitions differ by region. The National Cancer Institute uses fewer than 40,000 people diagnosed per year in the United States. Cancer Research UK reports that UK and EU experts use fewer than 6 cases per 100,000 people per year, with a lower threshold of fewer than 2 per 100,000 used when designing clinical trials. All childhood cancers are rare by these definitions.
Why is there no standard treatment for my cancer?
Standards of care are built from randomised trials, and randomised trials need enough patients. For tumours diagnosed in a few hundred people a year, that evidence usually does not exist. Recommendations are instead built from case series, registry data and expert consensus, which is why two specialists can disagree while both reasoning honestly.
Is a second opinion on the pathology worth it?
For rare tumours it is routine rather than adversarial. Diagnosis often depends on features a general pathologist may rarely encounter, and specialist centres frequently consult colleagues at other hospitals or in other countries. Since the treatment plan follows from the diagnosis, confirming the diagnosis first is the higher-leverage step.
How do I find anyone else with my diagnosis?
Disease-specific foundations and patient registries are the usual route, and many exist for individual rare tumour types. Specialist centres also concentrate patients, so attending one increases the chance of meeting others. Cancer Research UK notes explicitly that people with rare cancers may not know anyone else with their type.
Do I have to travel for treatment?
Often, at least for the initial assessment and planning. Cancer Research UK lists travel to a specialist hospital as a recognised burden of rare cancer care. Some centres will plan treatment remotely and let local services deliver it, which is worth asking about directly.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the federal sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Written by: Cancer Explained Editorial TeamSources last checked: 2026-07-30Last updated: 2026-07-30Next planned review: 2028-07-29
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source verified. This page was created with AI assistance and checked against the sources listed on it. Source checking is not a medical review.
General education. Low-risk educational or organizational content. Medical facts are cited to authoritative sources.
Human medical review: not completed. Cancer Explained is not clinician-reviewed, and that is a deliberate design choice rather than a gap we are waiting to close. We restate published federal guidance and cite it; the authority belongs to the source, not to us. That is why every page names where its claims come from — so you can verify us instead of trusting us. Use it to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source verified — This page was created with AI assistance and checked against the sources listed on it. Source checking is not a medical review.
Human medical review: not completed. Cancer Explained is not clinician-reviewed, and that is a deliberate design choice rather than a gap we are waiting to close. We restate published federal guidance and cite it; the authority belongs to the source, not to us. That is why every page names where its claims come from — so you can verify us instead of trusting us. Use it to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share